Scholar Rock Exec Says Its First Drug To Target Muscle Loss In Spinal Mus­cu­lar At­ro­phy Has A Wholesale Acquisition Cost Of $11,659 For A Single Use Vial; Exec Says Co Expects The Annual Net Cost In The U.S. For A Typical Patient To Be ~$310,000

This 8-K filing, based on a conference call, discloses the wholesale acquisition cost (WAC) and estimated annual net cost for Scholar Rock's first drug targeting muscle loss in Spinal Muscular Atrophy (SMA). The WAC is $11,659 per single-use vial, with an anticipated annual net cost of approximately $310,000 per patient in the U.S. This information provides initial pricing details for a key product, which is moderately market-moving for the company.

The filing indicates that a Scholar Rock executive, during a conference call, revealed the wholesale acquisition cost (WAC) of their new SMA drug to be $11,659 per vial and the expected annual net cost in the U.S. for a typical patient to be around $310,000. This is significant as it provides the first public indication of the drug's pricing structure, which is crucial for revenue projections and market access. While the pricing is now known, the market's reaction will depend on how this cost compares to existing SMA treatments and the drug's efficacy. For traders, this offers a baseline for future revenue modeling, with short-term implications tied to analyst reactions and long-term implications for the drug's commercial success and competitive landscape.